Scarica l'app Stockscreener
94.86
0.22%
-0.21
Dopo l'orario di chiusura:
96.00
1.14
+1.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Precedente Chiudi:
$95.07
Aprire:
$96.44
Volume 24 ore:
1.47M
Relative Volume:
0.45
Capitalizzazione di mercato:
$18.80B
Reddito:
$742.00K
Utile/perdita netta:
$-1.13B
Rapporto P/E:
-16.03
EPS:
-5.9165
Flusso di cassa netto:
$-913.73M
1 W Prestazione:
-3.60%
1M Prestazione:
-1.51%
6M Prestazione:
+103.78%
1 anno Prestazione:
+143.04%
Intervallo 1D:
$94.67
$99.09
Intervallo di 1 settimana:
$94.67
$101.38
Portata 52W:
$29.17
$124.49
Revolution Medicines Inc Stock (RVMD) Company Profile
Nome
Revolution Medicines Inc
Settore
Industria
Telefono
650-481-6801
Indirizzo
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
94.86 | 18.80B | 742.00K | -1.13B | -913.73M | -5.9165 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Ripresa | UBS | Buy |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-09-12 | Ripresa | Raymond James | Strong Buy |
| 2025-09-05 | Iniziato | Truist | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-08-15 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2024-07-16 | Reiterato | Needham | Buy |
| 2024-07-12 | Iniziato | Barclays | Overweight |
| 2024-07-08 | Iniziato | Jefferies | Buy |
| 2024-04-12 | Reiterato | Needham | Buy |
| 2024-04-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-04 | Iniziato | Wedbush | Outperform |
| 2023-11-16 | Iniziato | Raymond James | Outperform |
| 2023-02-28 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-10-21 | Iniziato | Oppenheimer | Outperform |
| 2022-05-20 | Iniziato | BofA Securities | Neutral |
| 2022-03-01 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-08-12 | Downgrade | Goldman | Buy → Neutral |
| 2021-05-18 | Iniziato | Goldman | Buy |
| 2020-05-21 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-09 | Iniziato | Cowen | Outperform |
| 2020-03-09 | Iniziato | Guggenheim | Buy |
| 2020-03-09 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Integral Health Asset Management LLC Has $18.68 Million Stock Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
General Atlantic L.P. Acquires New Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Director files Form 144 to sell RVMD shares (NASDAQ: RVMD) - Stock Titan
ETRADE (RVMD) Form 144 lists RSU grants and prospective resale activity - Stock Titan
Stephen Kelsey sold 5,447 shares — Revolution Medicines (NASDAQ: RVMD) - Stock Titan
Mark Goldsmith sells shares at Revolution Medicines (NASDAQ: RVMD) - Stock Titan
Insider sales reported at Revolution Medicines (NASDAQ: RVMD) — specific proceeds disclosed - Stock Titan
Victory Capital Management Inc. Trims Stock Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (RVMD) price target increased by 10.10% to 92.82 - MSN
A Look At Revolution Medicines (RVMD) Valuation After Recent Share Price Momentum - Yahoo Finance
Revolution Medicines’ Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations - MSN
Revolution Medicines gets FDA Breakthrough Therapy status for daraxonrasib - MSN
Bank of America Securities Remains a Buy on Revolution Medicines (RVMD) - The Globe and Mail
Why Revolution Medicines Inc. Equity Warrant stock is trending among retail tradersJuly 2025 Macro Moves & Daily Stock Momentum Reports - Naître et grandir
Earnings Report: Is Revolution Medicines Inc affected by consumer sentimentEarnings Recap Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
This One Data Readout Could Make Or Break Revolution Medicines (NASDAQ:RVMD) - Seeking Alpha
Is Revolution Medicines (RVMD) Pricing Fully Reflect Its Surging Oncology Pipeline Potential - simplywall.st
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Yahoo Finance
Handelsbanken Fonder AB Grows Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines Insider Sold Shares Worth $3,644,354, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines (NASDAQ:RVMD) Insider Mark Goldsmith Sells 30,000 Shares - MarketBeat
Revolution Medicines director Goldsmith sells shares worth $3.64 million - Investing.com Australia
Revolution Medicines (RVMD) officer receives new stock options and share grant - Stock Titan
Revolution Medicines (RVMD) grants CFO new stock and option awards - Stock Titan
Revolution Medicines (RVMD) GC receives 32,500-option and 14,500-share grants - Stock Titan
Revolution Medicines at TD Cowen Conference: Strategic Insights on Cancer Trials - Investing.com Australia
Revolution Medicines, Inc. $RVMD Shares Purchased by Legato Capital Management LLC - MarketBeat
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Rating of "Buy" from Brokerages - MarketBeat
RVMD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Revolution Medicines Doubles Down on Costly RAS Push - TipRanks
Broker proposes sale of 3,000 RVMD shares (NASDAQ: RVMD) — Form 144 - Stock Titan
Mark A. Goldsmith sells 15,394 shares (RVMD) via Form 144 - Stock Titan
Insider Form 144: 30,000-share option transaction for RVMD (RVMD) - Stock Titan
Revolution Medicines, Inc. (RVMD) Stock Analysis: Navigating the Highs of a 27% Potential Upside - DirectorsTalk Interviews
Revolution Medicines, Inc. $RVMD Shares Bought by Rafferty Asset Management LLC - MarketBeat
Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs - Insider Monkey
Can Revolution Medicines Inc outperform in the next rallyWeekly Volume Report & Weekly Top Performers Watchlists - baoquankhu1.vn
Revolution Medicines, Inc. $RVMD Shares Bought by TD Asset Management Inc - MarketBeat
UBS Adjusts Revolution Medicines Price Target to $145 From $71, Maintains Buy Rating - marketscreener.com
Is RVMD’s Big Losses and Massive Equity Plans Reshaping the Investment Case for Revolution Medicines (RVMD)? - Yahoo Finance
Truist Adjusts Price Target on Revolution Medicines to $116 From $99, Maintains Buy Rating - marketscreener.com
Revolution Medicines (NASDAQ:RVMD) Coverage Initiated at UBS Group - MarketBeat
Truist Raises Price Target on Revolution Medicines to $116 From $99, Keeps Buy Rating - marketscreener.com
Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating – Here’s Why - Insider Monkey
Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform RatingHere's Why - Bitget
RVMD Sees Target Price Uplift from Piper Sandler Analyst | RVMD Stock News - GuruFocus
Piper Sandler Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock - MarketBeat
Wells Fargo & Company Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $144.00 - MarketBeat
RVMD: Wells Fargo Raises Price Target to $144 with Overweight Ra - GuruFocus
Revolution Medicines (NASDAQ:RVMD) Shares Gap Down on Disappointing Earnings - MarketBeat
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View - Finviz
Revolution Medicines Inc Azioni (RVMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):